Background
Lithium's strikingly pervasive protective actions provide indirect evidence to support the existence of a set of latent, low cell [Mg ], which at critical times also appears to function as a metabolic "alarm signal". These systems would help to regulate, buffer, limit, and restore cell [Mg ++ ]. Li + therapy has the special advantage of being able to utilize these preexisting systems, as Li It is proposed that Li + and a low cell free [Mg ++ ] both activate the same proposed survival and recovery mechanisms, including the inhibition of the Li + -sensitive, and Mg ++ -dependent, inositol monophosphatase (IMPase)/inositol polyphosphate 1-phosphatase (IPPase), glycogen synthase kinase 3 (GSK-3), fructose-1,6-bisphosphatase (FBPase), bisphosphate nucleotidase (BPNase), phosphoglucomutase (PGM), adenylate cyclases, certain G-proteins, and beta-arrestin. Cell protection accumulates as cell [Mg ++ ] levels drop and/or as [Li + ] levels increase. Inositol depletion represents a more complex sub-mechanism, and in addition to lithium potentially limiting phospholipase C (PLC)-linked receptor systems, inositol
Introduction -existing models
There are two current, seemingly disconnected, partial theories of lithium's action.
The Berridge "inositol depletion" model [1] [2] [3] proposed that Li + was able to limit (notionally) "excess" signal transduction; as with the proposal here, this was based on the specific properties of certain key enzymes, as Li + inhibits both the IMPase and the related IPPase. 1, 2, 4 The kinetics of the IMPase appears well matched to the concentration of lithium used. 2, 4 The more recent GSK-3 theory noted that lithium is capable of exerting a powerful cascade of protective effects by inhibiting the important serine/threonine protein kinase. 5 The IMPase/IPPase and the GSK-3 enzymes are Mg ++ dependent. 2, [6] [7] [8] In both these systems, Li + acts via competition with Mg ++ . 2, [6] [7] [8] [9] The inositol reversible actions of mood stabilizers do not seem to involve GSK-3 inhibition, inositol-1-phosphate synthase, or inositol transporters, 10 and the inositol depletion hypothesis is considered to remain, as yet, unproven. 11 It appears unlikely that lithium's many pervasive effects, eg, on plasticity and survival, [12] [13] [14] [15] [16] can be dismissed, as merely coincidental.
The hydrated ionic radius of Mg
++ is similar to that of Li + . 6, 9 It has previously been suggested that competition between Li + and Mg ++ ions constitutes the ultimate (molecular) basis for the mechanism of action for Li + . 8, 9, [16] [17] [18] [19] Lithium can displace Mg ++ from some, but not all, binding sites within the (nerve) cell. 18 Lithium acts as a competitive inhibitor of numerous Mg ++ -dependent factors, transporters, and enzymes. 4 A hidden metabolic vulnerability forces the necessity for "low cell [Mg ++ ] failsafe mechanisms"? Lithium augments a cellular "protection racket"
The loss of cell protection following a significant drop in cell free [Mg ++ ] concentration (even if such a decrease were not associated with the probability of occurring alongside other adverse factors) would force the need for compensatory or more specialized cell protection.
It is proposed that the mood-stabilizing and protective effects of lithium are a consequence of lithium and/or a low cell [Mg ++ ], progressively activating a usually "dormant" set of latent cellular "fail-safe" protection/repair systems. By displacing Mg ++ ions at certain critical sites, lithium "imitates" and mimics a "lowered intracellular [Mg ++ ] level". The significance of lithium's wide-ranging actions 8, [12] [13] [14] [15] [16] needs to be re-interpreted, given the Mg ++ requirements (in the millimolar) physiological range of key members of an important family of enzymes.
The IMPase, inositol-1-phosphatase, acted on by Li +2 , belongs to a group of magnesium-dependent and lithiumsensitive phosphatases; this group includes IPPase, FBPase, and bisphosphate nucleotidase (BPNase). 21 Li + also inhibits the structurally unrelated PGM. 22 These enzymes are sensitive to Li + and require Mg ++ in relevant concentrations. 21 It is proposed that this family of enzymes, and GSK-3, provides the core of these "fail-safe" sub-mechanisms mobilized as ionized cell free magnesium [Mg ++ ] drops below the system's activation threshold, determined by the relevant enzymes' kinetics (see "The IMPase and IPPase" section), which are incidentally also further co-activated by lithium.
This may also present regulatory opportunities, as some Mg ++ -dependent enzymes can continue to function in the absence of Mg ++ , 23, 24 by using alternative cofactors, such as Mn ++ ions, but there appear to be changes in the properties of such enzymes, 23, 24 if the commonly used Mg ++ cofactor is substituted.
Mammalian cells maintain free cytosolic Mg ++ levels usually within the fairly narrow range of 0.5-1.1 mmol/L. 25, 26 Transport mechanisms and sequestration within cellular organelles contribute to this regulation; the binding of Mg ++ to a previously poorly defined system of buffers appears largely responsible for determining the "set point" of this regulation. [25] [26] [27] [28] [29] Brain ATP, which tends to chelate Mg
++
, is in the range of ~3.0 mmol/L. 30 
Mg
++ has actions in all the key systems where lithium has also been suspected of exerting its effects -ion channels, ATPases, G-proteins, cAMP, mitochondria, and phospholipids. 8, 16 Magnesium is required to activate some 300 enzymes and is fully integrated into cell function. [25] [26] [27] 31 Few clear-cut metabolic disturbances have been unequivocally established in magnesium deficiency; 29 which might suggest that intracellular Mg ++ may be specifically "privileged" and cell [Mg ++ ] may require special buffering regulatory arrangements as part of fail-safe cell protection systems. There appears to be a critical level of central nervous system (CNS) [Mg ++ ] concentration below which dysfunction appears to occur. 32 

++
, the common factor
The fail-safe model contains a second implied prediction that special situations would arise where such critically low cell [Mg ++ ] levels would occur. Indeed, in at least one situation, a large rapid severe decline in intracellular free [Mg ++ ] is known to occur (down to ~0.25 mmol/L) -about half the normal minimal level for a normal cell -which usually runs in the physiological range of 0.5-1.0 mmol/L 25, 26 and is associated with tissue injury and with a lowered cell [ATP] after TBI. [33] [34] [35] It is proposed that Li + augments latent homeostatic adaptations to increase cell resilience and the ability to adapt and survive in hazardous conditions accompanied by and associated with sub-optimal [Mg ++ ] levels, which also appear to reflect altered cell [ATP] levels.
Inositol depletion and its less considered inositol phosphate enhancement counterpart emerge as separate, semiindependent sub-components that -as well as appearing to help to regulate mood -also mediate cell protection. It is proposed that these protective mechanisms help regulate and stabilize intracellular [Mg ++ ] and (as Mg ++ forms a complex with ATP) help to stabilize cell energy levels, potentially at times also buffering any excess cell Mg
++
/Ca
++ and similar metal ions.
The role of the IMPase needs to be re-interpreted as representing a subtle fail-safe mechanism, compared to the more easily visible protective actions secondary to the inhibition of GSK-3. The new model also addresses lithium's action on other Mg ++ -requiring and Li + -sensitive systems -G-proteins, adenylate cyclase, beta-arrestin, 8, 12, 16, 36 etc. -and related aspects, including metal ion toxicity and various forms of excito-toxicity.
The implications for the modes of action of valproate and carbamazepine are discussed in outline.
Basic magnesium facts
The level of cytosolic and mitochondrial Mg ++ is partly maintained by binding to numerous low-affinity sites. [37] [38] [39] Neuropsychiatric Disease and Treatment 2017:13 submit your manuscript | www.dovepress.com
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Mg
++ also binds to ATP and inorganic phosphates, Pi, and also binds strongly to inorganic pyrophosphate (PPi). 37 The cell ratio of Mg ++ to Ca ++ seems to be about 2,000:1. Transport and sequestration within organelles appear to contribute to Mg ++ regulation; stable cell function seems to require a fairly stable cytosolic free [Mg ++ ] concentration. 40 The minutiae of cell Mg ++ homeostasis remain somewhat mysterious, 40 and changes in the "buffering system" seem to have an important role 38 consistent with preserving a homeostatic background. 40 Intracellular Mg ++ appears to have a permissive role, 40 supporting mechanisms mediated by Ca ++ . Mg ++ acts as a more long-term regulatory factor that "controls the set point or gain of a system". 39 The Li + effects on the GSK-3 variants, adenylate cyclases, G-proteins, and related beta-arrestin 8, 36 systems all operate by the same Li + competition with Mg ++ mechanism, 8 and as in the case of GSK-3, 6 other Mg ++ chelators, such as inositol phosphate, at relatively higher concentrations of ATP would be expected to further limit these enzymes. 6 Enzyme activity within this group will adapt to changes in the availability of Mg ] concentration had been reduced to compensate accordingly, providing a basic adaptive mechanism supporting more "exotic" fail-safe mechanisms.
The iMpase and ippase: more exotic failsafe mechanisms (Group 2)
The members of this key group of magnesium-dependent and lithium-sensitive phosphatases (particularly, the IMPase and IPPase) have the kinetics and specific properties that indicate that they have the ability to form subtle components of a low cell [Mg ++ ] fail-safe system; in effect, they also form part of a "low cell [Mg ++ ] management" and "sensing" system capable of activating more specialized forms of the "failsafe system" and appear to utilize various sub-mechanisms, including "InsPhosphate enhancement", and other related sub-mechanisms, eg, metal or ATP chelation (see ' ] also at times, appears to be recruited as an alarm signal to mobilize the maximal available (brain) cell protection (see 'The magnesium abyss' section).
The apparent linkage of this system to the response to TBI might appear to catastrophically fail to account for certain actions of Li + , eg, lithium's acute inhibition of glutamate reuptake 48 appears paradoxical, as it would tend to worsen the effects of excess glutamate-related excito-toxic activity, but remains relevant in a post TBI situation, as in the early phases of the post TBI situation, the normal direction of flow of membrane pumps -due to a severe lack of cell energy and membrane depolarization -actually appears to be reversed.
Within + also has the effect of "accreting" or "enhancing" the levels of myo-inositol monophosphates; 49 Ins1P, actually a collection of myo-inositol(4)P, Ins(1)P, plus Ins(3)P, and via also by inhibiting the IPPase; myo-inositol bisphosphate, Ins-(1,4)-bisphosphate, InsP2, 49 as well as CMP-PA, 50 and potentially other "minor" sugar phosphates including galactose-1P (see the 'Lithium's inhibition of PGM' section).
The implications of the rise in the levels of myoinositol phosphates -InsP1/InsP2 or various other sugar phosphates -seems to have been less explored as InsP is not a (conventional) "signaling molecule".
1,2 The consequent lithium-induced inositol phosphate enhancement or "sugar phosphate enhancement" is as real, and of the same general magnitude, as the simultaneously induced "inositol depletion", and a rise in InsP1 and InsP2 will simultaneously also trap -"deplete" -the corresponding finite amount of cell Pi (inorganic phosphate). The inhibition of the IMPase manifests as inositol depletion has the effect of creating inositol phosphate enhancement, which crucially generates additional cell Mg ++ -and Ca ++ -buffering capacity, as carbohydrate and cyclitol phosphates (sugar phosphates) are Ca ++ and Mg ++ metal-ion chelators ( Figure 1 ).
51,52
Key evidence: the matching Mg ++ and Li + kinetics of the iMpase, ippase, and GsK-3
Li
+ acts via an uncompetitive mechanism. Li + displaces an Mg ++ from the IMPase active site. 2, 4 The higher the concentration of substrate, the greater the degree of inhibition. 1, 2 Lithium acts as a competitive inhibitor of numerous Mg ++ -dependent factors, transporters, and enzymes. 4 ] concentration range, suggests that this may be part of a true regulatory system, with a system activation threshold below ~0.6-0.7 mmol/L, suggesting that in some cells, the system (including some background GSK-3 inhibition) may be partly operational during normal activity. A 0.8 mmol/L lithium is supposed to produce ~50% IMPase inhibition; 25, 26 Lithium has effects clinically observable at quite low concentrations, suggesting that there is not always any great surplus of brain IMPase activity, which appears to be thus effectively "rate-limiting"; this suggests that the prevailing intracellular It appears a challenge for the standard inositol depletion model that a mid-range of cell free [Mg ++ ] concentration appears to have the same degree of potential inhibitory (ratelimiting) activity on the IMPase as standard lithium therapy and will have the potential to produce the same potential degree of notional inositol depletion/"InsP enhancement" as a therapeutic concentration of lithium, ie, be moreor-less "equivalent" to Li + at least if the two different modes of inhibition -"uncompetitive" 50 versus a lack of an 
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Lithium utilizes cellular fail-safe mechanisms essential Mg ++ metal cofactor -does not skew this argument too greatly.
One obvious way that the system (say in "bipolar disorder") might become desensitized -and hence require boosting by Li + -is an increase in IMPase numbers. 54 The Gore et al 53 . The inositol cycle turnover appears to be set "too high" in the bipolar ("manic") disease state; 1, 2 it is this faster turnover that would permit a lack of the Mg ++ ion cofactor to limit IMPase enzyme activity.
Given the common core structure, 21 ' The magnesium abyss' section) -an at least 50% inhibition of the IPPase; note also that if the IMPase were a mutant -a non-Li + -sensitive form -it would then require a further mutation of the IPPase to lose all protection (at least via the inositol depletion/InsP enhancement mechanism), ie, it implies that even "non-lithiumsensitive" subjects would still preserve a residual degree of protection, eg, against TBI, but the protection would be inferior. This predicts that poor or non-Li + responders akin to "schizophrenics" would tend to do worse post head injury-type brain insults.
A + -like activity, why then should lithium ever be required? It seems to be only in those with sufficient vulnerability to mood disorders that this becomes critical, as the system of an intrinsic, lithium-like mood-stabilizing action may be working perfectly well in those -the bulk of the population -who remain "resilient".
The proposed mechanism offers an elegant, selective, "automatic" mood-stabilizing, and cell-resilience mechanism regardless of the minutiae of the mode of action. The in-built potential Li + -like action of a mid-range Mg ++ concentration on the IMPase, suggested by the Gore et al 53 kinetics, provides an in-built survival advantage to the organism, a high degree of innate resilience mood stabilization and multifaceted cell protection. The buffering system may carry some biological costs, which may create a potential for mood swings. The cell death/atrophy that appears at risk of occurring in mood disorders has been conceptualized as arising from an impairment of "cell resiliency". 57 If the IMPase numbers were to increase a few times, an excess of myo-inositol would then leak past the blockade and the proposed "buffering/depletion system" would start to break down. Harwood 54 proposed that changes in IMPase numbers are a key variable -an important interface between genetic and environmental factors determining vulnerability to mood disorders.
The way the system seems to work suggests that an increase in IMPase numbers would be fundamental to the in-built regulation -the innate mood stabilizing, cell protection, and "resiliency" -the protection provided by the IMPase, IPPase, and enzyme kinetics, and the regulation of ++ chelation/buffering system, and in the case of calcium, helping to act as a potential Ca ++ -"firewall"; to clamp, and limit the travel of excessive local Ca ++ "spikes". A mixture of various sugar phosphates, including G-6-P and galactose-1-P, inositol phosphates (Ins1P, InsP2, Ins-1,4P), and the higher Ins-phosphates would provide a potentially flexible Mg ++ and Ca ++ buffering subsystem. Galactose phosphate is also a form of IMPase substrate and IMPase inhibitor and has been proposed as a potential regulator of the IMPase. 59 Lutrell 51, 52 noted that affinity increases with the number of phosphate substituents on the sugar ring and suggested that the stereochemistry would also be relevant. Lutrell 51 suggested that for the relevant various inositol phosphates, half-maximal Ca ++ binding would occur in the concentration range of ~5×10 -6 to 2×10 -4 M. 51, 52 Lithium also causes an increase in cytidine monophosphoryl phosphatidate (CMP-PA), which in conditions of reduced inositol availability also tends to accumulate 50 another -albeit, a membrane-bound -Mg ++ -binding agent. This would appear to represent a complex buffering system, also involving, eg, creatine phosphate, F-1,6,-biphosphate, ATP/ADP, and citrate, most obviously relevant to higher cell energy states, probably binding Mg ++ at higher energy levels -at higher [ ]. An inability to properly buffer cell Ca ++ may cause toxic cell injury and compromise cell viability. 57 The proposed system would also tend to chelate -protect against other potentially toxic cations, Fe, Mn, Zn, Cu, Al, etc. 60 The various other "minor sugar phosphates" (perhaps particularly galactose-P) could potentially also act as nearequivalent Mg
++
/Ca
++ buffers in place of InsP1/P2. Further, pentose phosphate pathway (PPP)-derived minor sugar phosphate products are likely to increase in the event of a rise in ROS, which stimulates the PPP activity. Is it possible that a rise in minor sugar phosphates could potentially be adjunctive (somewhat equivalent) to Ins-phosphate in neurons, in terms of Mg
++
/Ca
++ buffering, potential IMPase substrate inhibiting, and/or also providing indirect antioxidant action (via toxic metal-ion binding), 60 even possible a further regulatory action (the activity of PI synthase in yeast, which competes with PS synthase, is elevated in zinc-deficient cells, so that InsP, if it chelates zinc, might help regulate [increase] PI synthase activity).
Chelating agents, binding copper or iron, appear to have (indirect) antioxidant effects 60 and are also able to block hydrogen peroxide formation caused by amyloid (and by potentially binding (eg, Cu/Zn) metal ions that might help precipitate abnormal folding of unstable proteins), so that the proposed inducible "low [Mg ++ ], InsP chelating mechanism" may offer wider protective properties, potentially limiting damage from high Ca ++ , and its consequences, or other toxic metals, eg, in abnormal protein-folding conditions, such as Alzheimer's (which also suggest that conditions of low cell [Mg ++ ] might be relevant to this) 61 (see "Conformational disease, protein folding" section).
Lithium -if it sets up a reservoir of Ins-phosphates, in some cells, under certain circumstances (particularly with cell [Mg ++ ] depletion, alongside its actions via GSK-3) -might also shift cell protein phosphorylation patterns and, by depleting Pi (inorganic phosphate), also tend to limit ATP, high energy-phosphate formation (and might potentially help to tend to shunt part of a finite pool of Pi away from, eg, a Tau hyper-phosphorylation "accident"). Compounds that stabilize intracellular [Ca ++ ] protect against Alzheimer's 61 inhibition of inositol 1,4,5-trisphosphate binding to its receptor by InsP chelation might limit InsP3-mediated increases in intracellular Ca ++ . 51, 52 If turnover is slow, there might be a reduced potential for Ins-P/sugar phosphate accumulation; hence, there would be less scope to safely "shunt" any excess cell phosphate if there is any relative "surplus" of Pi, which could increase potential risk of Tau hyper-phosphorylation.
As well as the various inositol phosphates and G-6-P, there is group of further "minor" Phosphor-sugars; these are interesting, as potential "analogues" of InsP1; as additional further substrates 62 of the IMPase -including G-3-P, (the PPP related); erythrose 4-P, ribose 5-P, G6-P, FBP, F6-P, xylose 5-P, galactose-1/6-P, and similar compounds.
The IMPase has evolutionary links to glycolysis; the IMPase is a highly conserved enzyme, with localized structural similarity to glycerol 3-phosphate dehydrogenase. 62 There are also structural similarities between FBPase and the IMPase. 63 The type 1 "IMPase" appears to be a curiously non-specific phospho-sugar phosphatase -an important clue to the deeper meaning of the original proposal.
The chemical similarity of these small sugar phosphate molecules, which also make up part of the PME peak, 50 suggests that they might complement the substrate-like, "grid-lock"-like action of InsP and could perhaps have relevant similar or additional/complementary inhibitory effects on the uncompetitively acting IMPase(s)/(and possibly act on further [Mg ++ ]-related downstream systems, eg, the CDP-PI synthase)? Note the possibility that such "substrate inhibition" might potentially still apply to some other, non-type 1 IMPase, non-lithium-sensitive, mutant IMPase variants. Potentially, the buffering from the "minor sugar phosphates", related to the PPP (perhaps particularly galactose-P) would appear to represent additional, constitutive components of the system that would not require receptor drive, or "fast" turnover, to set up or maintain.
There is the possibility that similar "minor sugar phosphates" also accumulate, as further (Ins-P like) "pseudo"-substrates for the IMPase/IPPase; if their concentrations become sufficient, these could also exert additional, Ins-Plike substrate inhibition on the IMPase, potentially further modulating turnover, or inhibiting, or possibly directly acting on or inhibiting various steps in the Ins-phosphate cycle, perhaps including ion channels. 49 also suggested that this uncompetitive method of blocking the IMPase is possibly as important as its target -as it enables a large increase in InsP1 (and similar substrate) levels, particularly in putatively "overactive"/"overstimulated" cells. This may explain an unusual feature of the IMPase enzyme, which has been likened by Berridge et al 3 to an inertia "seat-belt"-like mechanism. It may also explain the paradox that chronic lithium seems not always to greatly affect cell inositol or Ins-P. 66 Lithium would have, and would need to have, little effect in cells with normal [Mg ++ ] and "normal" levels of (receptor) turnover. Consistent with the proposed role of this system in TBI, the mode of action of IMPase seems more akin to a "damage limitation" system rather than adapted to steady-state inhibition. Several studies suggest that inositol depletion is not always a long-term phenomenon. 66 71 Lithium reduces the suicide rate more efficiently than other treatments; 72 Li + also normalizes the death rate from cardiac and other medical causes, 73 reflecting its broader protective actions. An inability to buffer cell Ca ++ may cause cell injury and compromise long-term cell viability. 57 Magnesium, predictably, has mood-stabilizing properties. 74 Heiden et al 75 33, 34 This decline typically persists for at least 4 days after TBI and with increasing severity of injury up to 7 days. 33, 34 Such a drop in the context of cell damage appears highly paradoxical as the electrochemical equilibrium potential for cellular free [Mg ++ ] is much higher -50 mM in most mammalian cells. 80 TBI does not appear to need to involve any actual brain ischemia, 81 ,82 yet involves a complex, severe metabolic crisis, with a reduction of oxidative metabolism, thought to be due to a Ca ++ -mediated impairment of mitochondrial respiratory function, a short-lived increase in glucose utilization, low oxygen extraction, increased lactate production, a tendency to induce secondary cytokine release, etc. 82, 83 Mild head injury is difficult to avoid; there is evidence that it occurs even with "normal" birth.
It The formation of PRPP generates AMP and consumes ribose-5P and ATP. Consumption of ribose-5P will tend to stimulate the PPP.
PRPP synthase has been linked to the actions of Li + and valproate in yeast models. 88 Yeast PRPP synthases appear to interact with GSK-3. 88 In yeast, the structurally intriguingly similar Ins-pyrophosphates regulate mitochondria and ATP formation. 89 PRPP is a biosynthetic precursor of GTP, riboflavin, and tryptophan; it is essential, and limiting, for both the de novo and the salvage pathways of purine, pyrimidine, and pyridine (NAD+, NADP+) nucleotides, [83] [84] [85] [86] [87] [90] [91] [92] so that PRPP availability will influence NAD availability, as well as affecting the availability of related (including potentially excito-toxic) tryptophan products. 93 The tryptophan product and, NAD precursor, quinolate can induce poly (ADP-ribose) polymerase (PARP) activation with subsequent intracellular NAD+ depletion and reduced ATP levels, leading to negative effects of mitochondrial permeability and overproduction of superoxide and nitric oxide. [93] [94] [95] [96] [97] NAMPT provides circadian rhythm control of NAD+ formation. PRPP is utilized to "detoxify" quinolate to nicotinate mononucleotide, and a reduction of this enzyme activity may contribute to seizures. 98 The important observation that mild TBI enhances receptor coupling, increases muscarinic-linked inositol phosphate production, in rat hippocampus, 99 103 and polyamines also co-chelate with ATP. 105 A low intracellular [Mg ++ ] in the early phases of an acute brain injury might shut down non-essential aspects of metabolism to conserve energy in a special situation, where normal mitochondrial, Ox-Phos, and ATP production is challenged, and would also tend to restrict cAMP dependent cell signaling, and by binding Ca ++ (which is increased after ATP depletion 105 ), tend to limit Ca ++ dependent PKC-DAG signaling, and perhaps somewhat limiting calcium release via the InsP3R as this requires a coincident Ca ++ signal, and via inositol depletion, and consequent membrane PIP2 depletion, and potentially further limit excito-toxic signaling, etc.
As the cell free Mg ++ drops, the IMPase/IPPase (and GSK-3) activity will tend to become further limited by the lack of Mg ++ ; in the case of the IMPase/IPPase, assuming a sufficient level of turnover, more InsP is produced, which will tend to deplete Pi and chelate and bind the remaining cell Mg ], so as to continue to maintain the "cell protection signal", during the critical first few days of the early TBI repair phase; This also binding the equivalent inorganic phosphate, Pi, the formation of Ins-P also limiting the rise, and the extrusion of cell Mg ], and perhaps also having a useful osmotic effect equivalent to sequestering at least 4 mmol/L Pi not counting any additional InsP2 -a "bidentate" chelating agent, also formed.
Inositol has been construed as having an osmoregulatory role; potential osmotic benefits against the brain cell swelling post head injury could be derived by binding more phosphate to alternative sugars, including FBP, and the increased formation of astrocytic glycogen, also tending to lower the local intracellular molarity. Piron et al 107 have shown that Mg ++ contributes significantly to osmoregulation, modulating ion channel-PIP 2 interactions. Low extracellular glucose post head injury 108 is associated with poor outcome; however, increased glycogen formation has been demonstrated post head injury; this may provide evidence of TBI acting to reduce GSK-3 activity; in spite of the lower cell energy availability, TBI manages to increase the astrocytic glycogen formation. 
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van Woerkom neurons -is ~50-100 µmol, in the rat, InsP1 can over a few days rise to 4.4 mmol/L, 106 also reflecting a significant shift in a finite pool of cell Pi, implying a strong cell [Pi] depletion if the de-phosphorylation is blocked by Li + and if there is sufficient agonist drive -"fast turnover". Human brain inositol concentration -mainly non-neuronal -is ~9 mmol/L. 110 In spite of the experimental evidence concerning the neuroprotective effects of magnesium, [33] [34] [35] a trial of magnesium in patients with moderate or severe TBI was unable to show neuroprotective effects and even indicated a possibility of harm. 111 There is no lack of total magnesium in this situation, consistent with the idea that the low cell [Mg ++ ] may be used as a trigger; an alarm signal to activate a set of protective responses, the depletion of cell Mg ++ occurs paradoxically in the face of much reduced ATP production. 82, 83 Magnesium has been proposed to be effective in TBI; 35 it inhibits a number of the secondary injury factors. ]. TBI involves a mixture of mechanical damage, excitotoxicity, oxidative stress, inflammation, ATP depletion, and the depletion of the NAD+-type, co-enzyme pool, mitochondrial dysfunction and Ca ++ overload, secondary cytokine release, etc. 81, 82 Any post TBI repair system is a compromise evolved without the luxury of extra pre/post-treatment Mg ++ available. Giving additional Mg ++ , at the correct phase, might relieve some pathways that are otherwise needlessly limited. Perhaps, combining Mg ++ pre/post-treatment with lithium (±galactose) might perhaps potentially provide enhanced protection. The optimal actions are likely to vary with time as different repair mechanisms set in. Given the apparent biochemical sophistication of the proposed mechanisms, it is unsurprising that it has proved difficult to demonstrate more effective treatments in human TBI; 111 Li + protects against stroke and predictably is protective against TBI in mice. 113 
Brain insults as backdrops to mood disorder
The apparent potential for a sudden drop in cell Mg ++ levels to occur after TBI may be a more extreme case, utilizing the general mechanism, which may also operate less dramatically in the more chronic situation of a compromised cell [Mg ] occurs in patients with mitochondrial disease; this appears related to a relative failure of the respiratory chain. Lowered ATP and creatine kinase activity and lower creatine levels have been linked to depression. 114 There appears a lower cell energy, lower ATP, in depression. 18 Bipolar disorder is thought to reflect a form of mitochondrial dysfunction. [115] [116] [117] Hypoxia/ ischemia can induce mitochondrial free radical production; during ischemia, the kynurenine pathway is activated, leading to increased production of quinolinic acid. 94, 95 Mania has been reported after correction of sleep apnea. 118 Anxiety and psychosis are more common in individuals with sleep apnea. 119 White matter lesions observed in depression and bipolar disorder may provide evidence for ischemia or reperfusion damage. 12 Possible re-perfusion injury is suggested by migraine occurring in a high proportion of patients with bipolar; reperfusion injury resembles migraine -a condition claimed to be associated with low brain 120, 121 Other causes of relative cell [ATP] depletion in mood disorders include factors increasing ROS, tending to deplete NAD+, NADPH, and GSH (reduced glutathione). Endotoxins and similar factors have the potential to derange mitochondrial electron transport, leading to disordered energy metabolism, even when enough oxygen is present. The degree of ATP and NAD+ impairment is likely to be less severe, but perhaps more long term in mood disorders, than post TBI, or following stroke, etc.
Reduced NAD+ availability induces a "pseudo-hypoxic" state 122 that contributes to a decline in mitochondrial function with age. Factors limiting the formation or depleting NAD will tend to deplete ATP, as NAD availability is required and appears limiting for mitochondrial ATP formation; eg, in circumstances where glucose is the main substrate, depletion of cytoplasmic NAD by 50% or more can block glycolysis and mitochondrial substrate flux. 123 The and Pi and to pull the intracellular inositol concentration (and the postulated small "active pool") of membrane PI/ PIP2 downwards, simultaneously tightening the inhibition of the IMPase, IPPase, and GSK-3, etc., in a positive feedback loop-optimizing cell protection.
A relatively large pool of intracellular neuronal InsP can accumulate. 106 Li + appears more effective at reducing elevated mood than lifting a low mood -the proposed mechanism suggests that the initial effect in increasing InsP is at first to clamp to lower the cell [ [Pi] , with effects on PPi exerting a potential shift in cell-protein phosphorylation patterns, and/or tending to limit the rate and amount of high energy phosphate formation, [124] [125] [126] potentially limiting mania, assuming mania may reflect a higher cell-energy level. The sequestration of Pi, eg, during the formation of galactose-1-phosphate in galactosemia, can limit ATP formation. 124 Presumably, the details of these mechanisms, including actions via cAMP, help to facilitate the longer-term restoration of both the cell [ PLC has always been conceptualized as providing a common pathway for cell signaling by the postulated hydrolysis of a small active pool of membrane phosphatidylinositol-4,5-bisphosphate (PtdInsP2) (PIP2), providing a dual output, InsP3, and a second associated DAG signal. There is a potential additional "third signal", the potential for the inactivation of TRPM7 -an important Mg ++ ion channel 26, [127] [128] [129] -which may be another potential further target of Li + action. PLCbeta, a signaling enzyme, 26, [127] [128] [129] [130] which utilizes the membrane PIP2 that would tend to be limited during inositol depletion, is directly coupled to TRPM7, 26, 128, 130, 131 which is a key Ca
++
and Mg ++ ion channel that during excito-toxicity, seems essential for mediating Ca ++ overload and to have a central role in both excito-toxic and non-excito-toxic neuronal death mechanisms, a broader protective role than protecting against just NMDA-mediated excito-toxicity. 26, 128, 129, 131, 132 This suggests that inositol depletion, rather than just limiting PLC-related receptor-based second messenger mechanisms, might potentially also act by also limiting associated Mg ++ (and Ca ++ )-related PIP2-dependent, PLC-coupled ion channels, which may provide additional mechanisms of further intrinsic protection related to (notionally) NMDA receptor-linked excess glutamate activity, but possibly actually mediated by a further related parallel Ca ++ and trace metal (perhaps including a zinc ion entry system). 26, 133 TRPM7 is an Mg ++ ion channel, an enzyme, a serine/ threonine kinase, and an "alpha kinase", related to eEF2 kinase 26, 129, 130, 133, 134 (required for cell survival under acute nutrient deprivation). 92, 130 eEF2 kinase is activated by AMP kinase and also appears linked to BDNF and to the action of ketamine in lifting mood. 134, 135 Neuropsychiatric Disease and Treatment 2017:13 submit your manuscript | www.dovepress.com
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van Woerkom TRPM7 has a functional role in survival under hypoxia or re-perfusion. 26, [127] [128] [129] 131 The kinase domain directly associates with the C2 domain of PLC. 130 This further links both the inositol depletion and "InsP enhancement" sub-mechanisms, to limit NMDA/glutamate-related excito-toxicity and the related free radical formation, an apparent vital common pathway in the origins of "psychosis".
TRPM7 activation is increased by ROS; its activity is promoted both by anoxia and excito-toxicity. 36, 131, 132 The inactivation of TRPM7 protects from Ca ++ overload and prolonged anoxia; intact TRPM7 function seems to be essential to mediate Ca ++ overload and consequent cell death. This TRPM7-mediated Ca ++ overload has been proposed to represent an essential component mechanism of excitotoxic cell death, associated with the "classical" NMDAglutamate mechanism (yet this appears to be a rather more complex mechanism), one that seems parallel to and which appears "dominant" to the "classical" pathway. 26, 127, [129] [130] [131] [132] The activation of TRPM7 requires a physiological level of ] concentration -with a suitable "chelating agent" 129 -results in a PLC-mediated inactivation of TRPM7, which appears mediated by a PIP(2) depletion. 26, 126, 128, 130 TRPM7 gating is downstream from NMDA, NO, and peroxynitrate-mediated free radical formation; TRPM7 suppression thus protects widely against a hazardous feedback loop involving Ca ++ influx and ROS. 26, [128] [129] [130] [131] The proposed "TRPM7 channel depletion" mechanism would complement the protection provided by Ca ++ /Mg ++ chelation due to the "enhancement" of InsPhosphate and/ or ("equivalent") sugar phosphates; these also increase in conditions of excess Ca ++ loading and consequent increased free radical formation due to changes in the flow of glucose toward the formation of PPP-derived metabolites.
An increased total cell metal chelation capacity will tend to further limit intracellular [ ] available to activate the IMPase, IPPase, GSK-3, etc., limiting their activity and reinforcing the inositol depletion and membrane PIP2 depletion (in a triple positive feedback loop) (as an increase in Ins-P, and/or sugar phosphates/ or Gal-P, will also tend to further increase inhibition of the IMPase/IPPase by increasing the IMPase substrate inhibition) -as these sugar phosphates, including galactose-P, 124 are also further competing IMPase substrates. ] have the potential to simultaneously limit both PIP2-dependent and the cAMP-based signaling systems.
Complexity and more "exotic" fail-safe mechanisms; lithium's inhibition of BpNase, pARp-1, pRpp, purines, NAD+, and ATp (Group 3)
There is the possibility that the inhibition of the other enzymes with the same common core structure -BPNase and FBPase, at least in the post TBI situation -may also provide protection in conditions associated with a limiting, low cell [Mg ++ ]. BPNase is both a 3′phosphoadenosine 5′-phosphate (PAP) phosphatase and an IPPase. 21 Over-activation of PARP-1, eg, post conditions resembling TBI, such as stroke or high glucose levels, leads to depletion of NAD(+) and then to depletion of ATP, leading to a critical cell-energy deficit. 136 Inhibition of the PAP phosphatase by lithium leads to increased levels of pAp (3′-5′ phosphoadenosine phosphate), which can inhibit PARP-1. 137 This action of lithium (or a low cell [Mg ++ ]), via limiting the BPNase, would help to prevent energy (ATP and NAD+) depletion.
PARP-1 and Mg ++ both help to maintain chromatin structure.
138,139 PARP1, in turn, induces ADP ribosylation of GAPDH -an enzyme that consumes NAD+, leading to its utilization -inactivation (not just a change in redox state) and an accumulation of glycolytic metabolites earlier in the pathway (which could have effects on minor sugar phosphate levels). PARP-1 activity is known to induce NO production. 140 Cerebral reperfusion injury induces GAPDH S-nitrosylation, 141 itself linked to NMDA receptor activation, so that lithium's inhibition, or limitation of the BPNase, creating increased levels of PAP, limiting the action of PARP-1, as well as limiting cell energy depletion, may offer broader cell protective actions.
Factors limiting formation or depleting NAD will also deplete ATP, as NAD availability is limiting for mitochondrial ATP formation. Valproate inhibits histone deacetylases 142 the inhibition of PARP-1 increases NAD enough to increase activity of SIRT1; sirtuins also use NAD to mediate deacetylation and ADP ribosylation, 94, 96, 97, [143] [144] [145] [146] so that the inhibition of deacetylases will also be able to modulate the availability of NAD+ and hence influence cell ATP supplies.
The first step in NAD+ synthesis is the formation of nicotinate ribonucleotide -from nicotinate and PRPP. PRPP also functions in several other ribosylating reactions.
The NAD+ precursor, and potent SIRT-1 inhibitor nicotinamide, 143 prevents NAD+ depletion and attenuates excito-toxic neuronal cell death. Irreversible NAD consumption by PARP-1 and SIRT1 may endanger energetically compromised neurons under conditions of reduced cell energy. SIRT1 may utilize enough NAD 146 to nullify any survival advantage from its deacetylase activity. PARP and sirtuin enzymes compete for the common NAD+ substrate; various key enzymes in the NAD+ salvage pathway regulate SIRT-1 activity. 97, 146, 147 Increased PP-Ribose-P, in enhancing purine salvage pathway activity, would help to preserve NAD+ and hence help protect cell [ATP] levels.
Relationship to the mode of action of valproate, pRpp and TBi
Valproate, like nicotinamide and butyrate, is a histone deacetylase inhibitor; 142 thus, valproate would help conserve both NAD and hence ATP during conditions where cell NAD becomes limiting. The conservation of NAD, and hence the preservation of cell [ATP], might be an important aspect of valproate's mode of action as a mood stabilizer.
NADP+ is required 148 for the formation of 4-hydroxybutanoic acid (GHB) 149 -GHB can reduce energy substrate consumption, and this has been implicated in the mode of action of valproate. 150 Zimmer 90 has shown that increasing the size of the tissue PRPP pool in rat heart, eg, using ribose, considerably increased the rate of restoration of cell [ATP] following various maneuvers, which decrease the ATP content; zur Nedden et al 151 have shown that both ribose and adenine help to restore post brain injury cell [ATP]; adenine can improve basal ATP in brain slices; the activity of the purine salvage (PRPP-related) pathways contribute to this restoration of cell [ATP] .
A lack of BDNF may contribute to depression. 152 Inosine is an important adenosine breakdown product and can bypass BDNF receptors. Inosine can act post-synaptically, mimicking BDNF. 134, 135 This begins to explain why inosine, hypoxanthine, and nicotinamide possess endogenous benzodiazepine ligand-like properties. 153 Inosine is formed extracellularly as a product of ATP breakdown. The loss of purines to the extracellular compartment risks the longlasting depletion of intracellular salvage metabolites, required to reform ATP; this again points to the importance of the salvage pathways in maintaining the long-term cell (ATP) levels; PRPP plays a key role in these salvage pathways. 90 Factors limiting the waste of NAD or its precursors -such as proposed here Li This may suggest that nicotinic acid and/or nicotinamide (the actions of which differ in detail), and perhaps adenine and ribose, might also have some potential valproate-like mood-stabilizing action. The situation in head injury, where PRPP (a precursor source of nucleotides) is formed in response to low ATP levels, enhancing pyrimidine salvage, 88, 143 helping to reduce potentially neurotoxic quinolate levels, is in stark contrast with that in cancer therapy, where after induction of a lowered cell [ATP] (induced by limiting NAD formation and/or by increasing the utilization of ATP by the activation of PARP), low [ATP] cell death is markedly enhanced by pyrimidine depletion, 121 ie, the combined effect of the cellular survival response post head injury (or post-Li + ) is opposite to that during attempts to kill cells using chemotherapy.
Nicotinamide is not only an NAD precursor and a product of sirtuin deacetylation 143 but also both a SIRT1 and a PARP-1 inhibitor. 96 Nicotinamide is a very effective deacetylase inhibitor. 96 Nicotinamide thus both increases NAD formation and reduces NAD utilization. It also protects against excito-toxicity. NAD protects against the effects of stroke. 96 Nicotinamide offers multiple protective mechanisms in stroke -as a precursor for NAD+, as a PARP inhibitor, and by partial restoration of mitochondrial function. 96 Valproate, like Li + , also protects against the effects of TBI 154 and cardiac anoxic damage. This also further links PRPP to serotonergic mechanisms, as de novo NAD+ synthesis is via the kynurenine pathway, and the breakdown of tryptophan increases NAD, notionally via the formation of quinolinic acid. Human nicotinamide availability is often marginal. 155 Shibata et al 155 demonstrated an increase in nicotinamide formation due to increased tryptophan breakdown induced by valproate, in rats. 155 Valproate has a further action in displacing tryptophan from plasma albumin; 156 this increases central kynurenic acid and tryptophan levels. 156 Valproate also increases liver NAD concentration. 155 Other short-chain fatty acids, 3-hydroxybutyrate, acetoacetate, and dietary fats, similar to valproate also increase central tryptophan levels 157 -displacing it from plasma albumin 147 and increasing tryptophan breakdown, to form more nicotinamide.
5HT re-uptake inhibitors reduce waste of 5HT precursors, so they might in part lift mood by an additional mechanism, enabling more NAD and related products such as nicotinamide to accumulate. Increased uric acid levels have been demonstrated in mania; this appears to be a true state marker for mania. 158 Lower serum phosphate levels have been found during anxiety and depression. 125 An adequate blood phosphate, [Pi] , level is required to maintain normal ATP metabolism. 126 Valproate, broadly mimicking a ketone body, by increasing nicotinamide formation from tryptophan, and limiting NAD consuming deacetylation reactions, would improve the NAD supply and hence tend to reduce the risk of [ATP] depletion.
Extracellular adenosine levels can rise after various metabolic stresses. 159 Adenosine can be released preemptively when there is a risk of ATP consumption outstripping ATP production; 159 the activation of adenosine receptors by the release of ATP activates A1 receptors, which helps reduce cell excitability to prevent potentially excessive energy demand arising. Carbamazepine may uprate adenosine A1 receptors. 160 Carbamazepine also tends to reduce cell cAMP concentrations. 161, 162 Preempting a cell energy crisis may be an alternative strategy. Carbamazepine could help prevent potentially overstimulated cells from becoming critically energy-depletednot because of excess PARP-1 and sirtuin-related, excess NAD utilization, but by limiting excessive "fast-firing" activity, and by reducing cAMP formation, 161 FBPase is usually construed as involved in gluconeogenesis; surprisingly, increased glycogen formation has been demonstrated post head injury, 108, 109 so that gluconeogenesis could still occur in (delayed) phases of such situations. FBP is an endogenous cell protective molecule; it facilitates recovery during hypoxia and ischemia and helps to stabilize intracellular Ca ++ . 165 FBP, a diffusible high-energy intermediate, is protective in many different systems. 165, 166 This cyto-protective activity has been described in many systems -reperfusion injury, sepsis, etc. 167, 168 Relating to the previous comments about PARP-1, as already noted, increased NO production inhibits GA3PDH via S-nitrosylation or by ADP ribosylation; this can modify the rate of formation of glycolytic intermediates, which leads, eg, in the gut, to increased tissue FBP accumulation; NO generated during pre-conditioning inhibits GA3PDH and leads to NO-dependent FBP accumulation. Inhibition of FBPase by Li + will tend to increase levels of FBP, particularly in conditions of increased NO production, such as post TBI.
FBP has strong anticonvulsant activity. 167 Low glutathione (GSH) levels appear to be associated with seizures. 158, 169 FBP, the precursor for glyceraldehyde-3P and DHAP, is an activator of the PPP and, by increasing synthesis of 6-phosphogluconate, activates the flow of G-6P to the PPP, 
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Lithium utilizes cellular fail-safe mechanisms helping to enhance NADPH formation to maintain GSH levels, and this tends to help raise seizure thresholds. 167, 169 FBP is also a chelating agent, binding Ca ++ and Fe (II). FBP improves metabolic efficiency, can affect apoptosis and second messenger release, 169 and helps preserve the intracellular glutathione and the ATP pool. 166, 170 These properties all appear useful in the proposed context of recovering from TBI. FBP appears to reduce Na+/K+ ATPase activity and reduces ATP turnover. 170 There is potential substrate cycling between fructose 6-phosphate (F-6P) and FBP. FBPase catalyzes the hydrolysis of FBP back to F-6P, a futile cycle, that wastes ATP and at times might help deal with excess [ATP] levels.
Lithium's inhibition of pGM (Group 5)
PGM itself is activated by glucose-1,6-biphosphate; a normal adult can produce up to 2 g/d of galactose; 124 thus, lithium (or a low cell [Mg ++ ]) will tend to slow the conversion of the galactose product G-1-P to G-6-P, and this results in a higher level of residual galactose and its product -galactose-1P, which is both an IMPase substrate and a competitive IMPase inhibitor -and will thus tend to increase both inositol depletion and increase InsP enhancement by adding to the substrate inhibition provided by the other similar minor sugar phosphates, as a build-up of excess Ins-P1-like substrate tends to increase the net inhibition of the IMPase, which will appear to increase the "lithium sensitivity".
Most galactose in breast milk comes from blood rather than local synthesis, having galactose available before birth might help to limit damage, associated with the intrinsic "mild TBI" of birth.
There is another futile cycle between galactose-phosphorylation and dephosphorylation; the latter is performed by the IMPase. Lithium's interference with galactose metabolism suggests that Li + treatment could potentially change calorie requirements and could also alter certain protein-glycosylation patterns, which might be relevant to immune changes, eg, the thyroiditis often seen post Li + ; this might provide the basis of potential future, in vitro, objective disease-state markers in mood disorders.
Conformational disease, protein folding: inositol depletion, Mg ++ , the unfolded protein response, and autophagy (Group 2/Group X) Mg ++ is involved in protein and RNA folding. Amylin misfolding may be magnesium dose dependent in diabetic patients. 171 If the depletion of cell ATP is severe, this can result in disruption of the protein synthetic structures, and if cells are deprived of oxygen or similar factors, proteins may become mis-folded. This may explain why Li + also has effects on systems related to the UPR. This area is complex and beyond the scope of this study, the UPR is signaled through various factors, including inositol-requiring protein 1α; within this system, Li + is again acting seemingly in this case, partly via a bulk, cytoplasmic inositol depletion mechanism, again, in competition with Mg ++ .
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Some clinical implications
Adding inositol to lithium therapy has been claimed to (paradoxically) improve depression and anxiety. 173 This argues against inositol depletion as the key or sole mechanism of action of Li + ; however, it is consistent with the idea, which the new model readily permits, that inositol depletion and inositol phosphate enhancement (and sugar phosphate enhancement) act as cooperative, semi-independent, sub-mechanisms.
The key concept that lithium may be (particularly adapted to) acting in a low [Mg ++ ] environment, as well as being congruent with the rationale for the proposed mechanism, removes some of the apparent paradoxes; it would require less stimulation to set up, or maintain InsP enhancement/ inositol depletion -note that InsP2 levels would also tend to increase -due to the (dual) inhibition of IPPase, due to low The difference between "high" or "low" mood may be due in part to which "driving" receptor systems in a particular network might be on or off the levels of extracellular and intracellular [ Increasing dietary Mg (assuming that there are no membrane transport problems) should tend to improve mood, reduce suicide risks, improve the response rate, and maintain stability and resilience. When lithium augmentation is used, it predicts that Mg ++ should tend to replace, or further augment antidepressants, even during lithium augmentation (more so, when IMPase numbers are increased). There are numerous variables, Mg/Mg ++ levels (both intra-and extracellular), [ATP-Mg] levels, Ca ++ , ATP/ADP/AMP, AMPK, CreatineP, Pi, PPi, NAD+, adenosine levels/ratios, IMPase numbers, turnover rate, pH, polyamines, the levels of various other buffering systems, redox states, mitochondrial competence, PPP activity, GSH, Na+/K+ ATPase inhibitory activity, osmotic factors, etc.
In some conditions, quite small levels of lithium, perhaps only as little as 0.2 mmol/L, appear to begin to be somewhat effective in prophylaxis and in augmenting mood, alongside antidepressants; yet more Li + seems required to subdue elevated mood, suggesting perhaps a lower cell [ATP] ] concentration management system, the potential for instability and "un-moderated" metabolic damage would seem greater; this may partly explain why "metabolic disorder risks" appear more "bloated" alongside the more common psychiatric disorders.
The expanded, "inositol depletion-Ins phosphate enhancement" model that emerges suggests that the inhibition by lithium (and/or a low Mg ++ level) of the IMPase, and related systems, is not at all wasteful and appears to make use of "everything"; both the inositol phosphate enhancement and the complimentary inositol depletion mechanisms, in the process potentially creating additional Mg ] level to optimize energetic-phosphor group transfer efficiency, prompting a need for specific arrangements to link cell-signaling to cell-energetics, and at times, actively buffer Pi and Mg ++ . The evidence of mitochondrial, glycolytic disturbances in bipolar suggests that cell energy disturbances will inevitably involve [ATP-Mg ++ ] and similar factors, including ATP breakdown products, eg, inosine acting on BDNFrelated systems. 128 It is possible that InsP/sugar phosphates interacting with the Mg bound to ATP (also linked to AMPkinase), affecting the efficiency of phosphate group energetic transfer, and like the two identified futile ATP cycles, may be relevant to weight gain. Various "minor sugar phosphates" would appear to represent components of the system that would not require strong receptor drive, or fast turnover, to maintain. Excess IMPase numbers may critically undermine mechanisms for innate resilience and unmask potential metabolic effects, consequent upon "unprotected" low cell Bipolar disorder may reflect the behavior of a disregulated mood regulating system, perhaps dis-regulated both at the level of mood and at the level of systemic metabolic effects. A core feature of mood disorders is an alteration of the systemic energy level; this should be reflected in disturbances of cell [ATP] and with factors closely related to ATP.
Given the broad range of protection apparently provided by Li + in mood disorders, the apparent lack of sensitivity to Li + in the schizophrenia(s) provides an important paradox, suggesting that there is less obviously an issue of an apparent "low cell [Mg 
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Lithium utilizes cellular fail-safe mechanisms to set up an effective, full proposed enhancement/depletion, Mg ++ /Ca ++ buffering system. This might force the adoption of an inferior, perhaps possibly polyamine-based cellular defense system; this may yield more motley symptoms, perhaps further complicated by further small mutations, whose effects might otherwise be masked and also expose a greater potential susceptibility to perinatal damage.
Conclusion: the "how" and the "why" of lithium action
The new model suggests that lithium therapy is pre-configured to be able to utilize cellular fail-safe mechanisms, enabling survival in pathological conditions, associated with the depletion of cell [ These systems appear pre-configured to optimize neuroprotection post TBI; following which, the brain cell [Mg ++ ] paradoxically drops to a critically low level.
The fail-safe model postulates the existence of a set of pre-programmed biochemical responses -"special measures" adapted to provide protection against mechanical trauma, brain injury, involving the activation of pathways sensitive to a low cell free [Mg ++ ] that appear to be "parasitically" utilized by lithium to generate its therapeutic effects.
These systems would also provide background protection and resilience to cells generally; this may also be relevant to cell survival in cancer and perhaps other states of altered cell [ The model permits a better understanding of links between cell energetics, mono-amine systems, and mechanisms underpinning cell resilience and mood stabilization.
Derived from a different premise, yet still based on the same kinetics, and the [Mg ++ ] dependency of this family of enzymes, the fail-safe concept spontaneously "transmogrifies" into a much expanded, inositol depletion-inositol phosphate enhancement-GSK-3 model, furnishing details that appear AWOL from earlier concepts.
An informative extension to both the inositol depletion and the GSK-3 models emerges, providing a new context, unifying and expanding existing concepts. The new model provides insights into the configuration of an unexpectedly subtle system, underpinning cellular aspects of mood. Further biochemical details will be addressed in a future paper.
